One ATR Kinase Inhibitor Mechanism, Three Gateways: What a Biomarker-Selected Oncology Candidate's Regulatory Path Reveals About Parallel Health Canada, FDA, and EMA Clinical Trial Authorization

Ataxia telangiectasia and Rad3-related protein (ATR) kinase inhibitors are investigational small molecules that target a central regulator of the cellular DNA damage response, exploiting the observation that tumours carrying certain loss-of-function alterations in DNA damage response pathways may